Paige Carpenetti
Medical · China Grove, NCNPI 1750839395
Payments from drug & device makers
Across 77 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250
- Lilly USA, LLC$209
- Novo Nordisk$174
- AstraZeneca$164
- Exact Sciences$147
- Bayer$141
- plus $398 from 13 others
What the payments were for
- Food & beverage$1,482100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $250 |
| Lilly USA, LLC | 12 | $209 |
| Novo Nordisk | 9 | $174 |
| AstraZeneca | 6 | $164 |
| Exact Sciences | 7 | $147 |
| Bayer | 8 | $141 |
| Gilead | 3 | $80 |
| Boehringer Ingelheim | 3 | $69 |
| Shield Therapeutics Inc | 3 | $46 |
| Cranial Technologies, Inc | 2 | $41 |
| Abbott | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Merck | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Organon | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$1,482 in reported general payments places this provider in the 70th percentile of 878 medical providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $70,297 |
| FarxigaDapagliflozin Propanediol | 24 | $26,472 |
| EliquisApixaban | 27 | $26,371 |
| JardianceEmpagliflozin | 20 | $21,201 |
| EntrestoSacubitril/Valsartan | 15 | $15,721 |
| MounjaroTirzepatide | 14 | $15,025 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,342 |
| TrulicityDulaglutide | 12 | $13,634 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $11,512 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,315 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,493 |
| Gabapentin | 57 | $1,234 |
| Ventolin HfaAlbuterol Sulfate | 12 | $984 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $677 |
| Atorvastatin Calcium | 128 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $174 | $70,29733 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $164 | $37,98437 claims |
| Lilly USA, LLCMounjaro, Trulicity | $209 | $28,65926 claims |
| PfizerEliquis | $17 | $26,37127 claims |
| Boehringer IngelheimJardiance | $69 | $21,20120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 878 medical providers in North Carolina.
Other medical in China Grove
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.